Literature DB >> 15361488

Early interactions of Salmonella enterica serovar typhimurium with human small intestinal epithelial explants.

A Haque1, F Bowe, R J Fitzhenry, G Frankel, M Thomson, R Heuschkel, S Murch, M P Stevens, T S Wallis, A D Phillips, G Dougan.   

Abstract

BACKGROUND: Salmonella enterica serovar typhimurium (S typhimurium) causes invasive gastroenteritis in humans, a disease involving significant penetration of the intestinal mucosa. However, few studies have been undertaken to investigate this interaction directly using differentiated human gut tissue. AIMS: To investigate the early interactions of an enteropathogenic strain of S typhimurium with human intestinal mucosa using human intestinal in vitro organ culture (IVOC).
METHODS: Wild-type and mutant derivatives of S typhimurium TML were used to compare interactions with cultured human epithelial cells, bovine ligated loops, and human intestinal IVOC.
RESULTS: S typhimurium TML was shown to attach to cultured Caco-2 brush border expressing cells and cause tissue damage and fluid accumulation in a ligated bovine loop model.S typhimurium TML bound predominantly to the mucus layer of human IVOC explants during the first four hours of IVOC incubation. From four to eight hours of IVOC incubation, small but characteristic foci of attaching and invading S typhimurium TML were detected as clusters of bacteria interacting with enterocytes, although there was no evidence for large scale invasion of explant tissues. Ruffling of enterocyte membranes associated with adherent Salmonella was visualised using electron microscopy.
CONCLUSIONS: Human IVOC can be used as an alternative model for monitoring the interactions between S typhimurium and human intestinal epithelium, thus potentially offering insight into the early stages of human Salmonella induced gastroenteritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361488      PMCID: PMC1774215          DOI: 10.1136/gut.2003.037382

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Site-directed mutagenesis of intimin alpha modulates intimin-mediated tissue tropism and host specificity.

Authors:  S Reece; C P Simmons; R J Fitzhenry; S Matthews; A D Phillips; G Dougan; G Frankel
Journal:  Mol Microbiol       Date:  2001-04       Impact factor: 3.501

Review 2.  Molecular basis of Salmonella-induced enteritis.

Authors:  T S Wallis; E E Galyov
Journal:  Mol Microbiol       Date:  2000-06       Impact factor: 3.501

3.  Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression.

Authors:  A T Gewirtz; T A Navas; S Lyons; P J Godowski; J L Madara
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

4.  Dendritic cells shuttle microbes across gut epithelial monolayers.

Authors:  M Rescigno; G Rotta; B Valzasina; P Ricciardi-Castagnoli
Journal:  Immunobiology       Date:  2001-12       Impact factor: 3.144

Review 5.  Salmonella interactions with host cells: type III secretion at work.

Authors:  J E Galán
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

6.  Proteolytic inhibition of Salmonella enterica serovar typhimurium-induced activation of the mitogen-activated protein kinases ERK and JNK in cultured human intestinal cells.

Authors:  Tracey L Mynott; Ben Crossett; S Radhika Prathalingam
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

7.  Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells.

Authors:  Y Chowers; L Cahalon; M Lahav; H Schor; R Tal; S Bar-Meir; M Levite
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

8.  Enterohaemorrhagic Escherichia coli O157:H7 target Peyer's patches in humans and cause attaching/effacing lesions in both human and bovine intestine.

Authors:  A D Phillips; S Navabpour; S Hicks; G Dougan; T Wallis; G Frankel
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

9.  Tissue tropism of enteropathogenic Escherichia coli strains belonging to the O55 serogroup.

Authors:  R J Fitzhenry; S Reece; L R Trabulsi; R Heuschkel; S Murch; M Thomson; G Frankel; A D Phillips
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

10.  Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

Authors:  Zoë Hindle; Steven N Chatfield; Jo Phillimore; Matthew Bentley; Julie Johnson; Catherine A Cosgrove; Marjan Ghaem-Maghami; Amy Sexton; Mohammad Khan; Frank R Brennan; Paul Everest; Tao Wu; Derek Pickard; David W Holden; Gordon Dougan; George E Griffin; Deborah House; Joseph D Santangelo; Shahid A Khan; Jaqueline E Shea; Robert G Feldman; David J M Lewis
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

View more
  19 in total

1.  The Ex Vivo Colon Organ Culture and Its Use in Antimicrobial Host Defense Studies.

Authors:  S M Nashir Udden; Sumyya Waliullah; Melanie Harris; Hasan Zaki
Journal:  J Vis Exp       Date:  2017-02-13       Impact factor: 1.355

Review 2.  Pathogenesis of human enterovirulent bacteria: lessons from cultured, fully differentiated human colon cancer cell lines.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Microbiol Mol Biol Rev       Date:  2013-09       Impact factor: 11.056

3.  Morphologic and cytokine profile characterization of Salmonella enterica serovar typhimurium infection in calves with bovine leukocyte adhesion deficiency.

Authors:  J S Nunes; S D Lawhon; C A Rossetti; S Khare; J F Figueiredo; T Gull; R C Burghardt; A J Bäumler; R M Tsolis; H L Andrews-Polymenis; L G Adams
Journal:  Vet Pathol       Date:  2009-12-31       Impact factor: 2.221

4.  Salmonella enterica serovar Typhimurium pathogenicity island 2 is necessary for complete virulence in a mouse model of infectious enterocolitis.

Authors:  Bryan Coburn; Yuling Li; David Owen; Bruce A Vallance; B Brett Finlay
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

5.  The Vi capsular antigen of Salmonella enterica serotype Typhi reduces Toll-like receptor-dependent interleukin-8 expression in the intestinal mucosa.

Authors:  Manuela Raffatellu; Daniela Chessa; R Paul Wilson; Richard Dusold; Salvatore Rubino; Andreas J Bäumler
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

6.  Response of porcine intestinal in vitro organ culture tissues following exposure to Lactobacillus plantarum JC1 and Salmonella enterica serovar Typhimurium SL1344.

Authors:  J W Collins; N G Coldham; F J Salguero; W A Cooley; W R Newell; R A Rastall; G R Gibson; M J Woodward; R M La Ragione
Journal:  Appl Environ Microbiol       Date:  2010-07-16       Impact factor: 4.792

7.  CfaE tip mutations in enterotoxigenic Escherichia coli CFA/I fimbriae define critical human intestinal binding sites.

Authors:  K K Baker; M M Levine; J Morison; A Phillips; E M Barry
Journal:  Cell Microbiol       Date:  2009-01-15       Impact factor: 3.715

8.  Salmonella enterica serovar enteritidis pathogenicity island 1 is not essential for but facilitates rapid systemic spread in chickens.

Authors:  Taseen S Desin; Po-King S Lam; Birgit Koch; Claudia Mickael; Emil Berberov; Amanda L S Wisner; Hugh G G Townsend; Andrew A Potter; Wolfgang Köster
Journal:  Infect Immun       Date:  2009-04-13       Impact factor: 3.441

9.  A tertiary amino-containing polymethacrylate polymer protects mucus-covered intestinal epithelial monolayers against pathogenic challenge.

Authors:  Simon Keely; Lee-Anne B Rawlinson; David M Haddleton; David J Brayden
Journal:  Pharm Res       Date:  2007-11-29       Impact factor: 4.200

10.  In vitro interactions between the oral absorption promoter, sodium caprate (C(10)) and S. typhimurium in rat intestinal ileal mucosae.

Authors:  Alyssa B Cox; Lee-Anne Rawlinson; Alan W Baird; Victoria Bzik; David J Brayden
Journal:  Pharm Res       Date:  2007-06-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.